Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 3/2017

01-03-2017 | Cases with a Message

Posterior reversible encephalopathy syndrome in Henoch–Schönlein purpura

Authors: Sebastiano A. G. Lava, Gabriëlla G. A. M. Peeters, Mario G. Bianchetti, Barbara Goeggel Simonetti, Giacomo D. Simonetti, Gregorio P. Milani

Published in: Rheumatology International | Issue 3/2017

Login to get access

Excerpt

To the Editor, …
Literature
1.
Fugate JE, Rabinstein AA (2015) Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 14:914–925CrossRefPubMed
2.
Santuari E, Simonetti GD (2016) La porpora di Schönlein–Henoch e il coinvolgimento renale in età pediatrica. Trib Med Tic 81:27–29
3.
Woolfenden AR, Hukin J, Poskitt KJ, Connolly MB (1998) Encephalopathy complicating Henoch–Schönlein purpura: reversible MRI changes. Pediatr Neurol 19:74–77CrossRefPubMed
4.
Özcakar ZB, Ekim M, Fitoz S et al (2004) Hypertension induced reversible posterior leukoencephalopathy syndrome: a report of two cases. Eur J Pediatr 163:728–730CrossRefPubMed
5.
Sasayama D, Shimojima Y, Gono T, Kaneko K, Matsuda M, Ikeda S (2007) Henoch–Schönlein purpura nephritis complicated by reversible posterior leukoencephalopathy syndrome. Clin Rheumatol 26:1761–1763CrossRefPubMed
6.
Salloum AC, Cuisset JM, Vermelle M, Loeuille GA, Mukuna D, Blanckaert D (2009) Encéphalopathie postérieure reversible compliquant un purpura rhumatoïde: présentation d’un cas. Arch Pédiatr 16:284–286CrossRefPubMed
7.
Dasarathi M, Birchall D, De San Lazaro C et al (2012) Henoch–Schönlein purpura with posterior reversible encephalopathy syndrome. Pediatr Neurol 46:42–43CrossRefPubMed
8.
Montaner J, Molina C, Alvarez-Sabín J, Ordi J (2000) Manifestaciones neurológicas en la púrpura de Schönlein–Henoch: ¿vasculitis cerebral o leucoencefalopatía posterior reversible? Med Clin (Barc) 115:677CrossRef
9.
Fuchigami T, Inamo Y, Hashimoto K et al (2010) Henoch–Schönlein purpura complicated by reversible posterior leukoencephalopathy syndrome. Pediatr Emerg Care 26:583–585CrossRefPubMed
10.
Endo A, Fuchigami T, Hasegawa M et al (2012) Posterior reversible encephalopathy syndrome in childhood: report of four cases and review of the literature. Pediatr Emerg Care 28:153–157CrossRefPubMed
11.
Sivrioglu AK, Incedayi M, Mutlu H et al (2013) Posterior reversible encephalopathy syndrome in a child with Henoch–Schonlein purpura. BMJ Case Rep. pii: bcr2013008900
12.
Stefek B, Beck M, Ioffreda M et al (2015) Henoch–Schönlein purpura with posterior reversible encephalopathy syndrome. J Pediatr 167:1152–1154CrossRefPubMed
13.
Fidan K, Kandur Y, Ucar M, Gucuyener K, Soylemezoglu O (2016) Posterior reversible encephalopathy syndrome in Henoch–Schonlein purpura and hemolytic uremic syndrome. J Clin Med Res 8:544–547CrossRefPubMedPubMedCentral
14.
Erol M, Fucucuoğlu D, Kutanis E, Yiğiit O, Gayret OB, Albayrak R (2015) Posterior reversible encephalopathy syndrome associated with Henoch–Schönlein purpura. ZKTB 46:4
15.
Ha TS, Cha SH (1996) Cerebral vasculitis in Henoch–Schönlein purpura: a case report with sequential magnetic resonance imaging. Pediatr Nephrol 10:634–636CrossRefPubMed
16.
Fösel S, Artmann H (1990) Schwere Encephalopathie bei Purpura Schönlein–Henoch (Fallbericht). Klin Pädiatr 202:109–111CrossRefPubMed
17.
Pavlou E, Hatzistilianou M, Stamou M et al (2010) Posterior reversible encephalopathy syndrome in Henoch–Schönlein purpura induced by oral steroid therapy and hypertension. J Pediatr Neurol 8:421–424
18.
Kim KY, Jung MK, Kim KH et al (2014) A case of Henoch–Schönlein purpura associated with posterior reversible encephalopathy and review of literature. Pediatr Rheumatol 12(Suppl 1):358CrossRef
19.
Khokhar HV, Choudhary P, Saxena S, Arif M (2016) Posterior reversible encephalopathy syndrome with spinal cord involvement (PRES-SCI): a case report. Ann Indian Acad Neurol 19:134–136CrossRefPubMedPubMedCentral
20.
Garzoni L, Vanoni F, Rizzi M et al (2009) Nervous system dysfunction in Henoch–Schonlein syndrome: systematic review of the literature. Rheumatology (Oxford) 48:1524–1529CrossRef
Metadata
Title
Posterior reversible encephalopathy syndrome in Henoch–Schönlein purpura
Authors
Sebastiano A. G. Lava
Gabriëlla G. A. M. Peeters
Mario G. Bianchetti
Barbara Goeggel Simonetti
Giacomo D. Simonetti
Gregorio P. Milani
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3577-1

Other articles of this Issue 3/2017

Rheumatology International 3/2017 Go to the issue

Therapy Review

Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?

Genes and Disease

Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose

Health Services Research

SCORE study: quality indicators for rheumatology nursing clinics

Review on Health Services

A critical review of complementary and alternative medicine use among people with arthritis: a focus upon prevalence, cost, user profiles, motivation, decision-making, perceived benefits and communication

Safety and Pharmacovigilance

Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis

Genes and Disease

Identification of potential peripheral blood diagnostic biomarkers for patients with juvenile idiopathic arthritis by bioinformatics analysis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits